Discovery, Preclinical Characterization, and Early Clinical Activity of JDQ443, a Structurally Novel, Potent, and Selective Covalent Oral Inhibitor of KRASG12C
Open accessPublished version of a preprint
The DOI matches its Crossref record; 55 of the 60 references it cites were found in a registry or an index; 12 of the 42 sources its claims cite were checked for support.
Abstract
Covalent inhibitors of KRASG12C have shown antitumor activity against advanced/metastatic KRASG12C-mutated cancers, though resistance emerges and additional strategies are needed to improve outcomes. JDQ443 is a structurally unique covalent inhibitor of GDP-bound KRASG12C that forms novel interactions with the switch II pocket. JDQ443 potently inhibits KRASG12C-driven cellular signaling and demonstrates selective antiproliferative activity in KRASG12C-mutated cell lines, including those with G12C/H95 double mutations. In vivo, JDQ443 induces AUC exposure-driven antitumor efficacy in KRASG12C-mutated cell-derived (CDX) and patient-derived (PDX) tumor xenografts. In PDX models, single-agent JDQ443 activity is enhanced by combination with inhibitors of SHP2, MEK, or CDK4/6. Notably, the benefit of JDQ443 plus the SHP2 inhibitor TNO155 is maintained at reduced doses of either agent in CDX models, consistent with mechanistic synergy. JDQ443 is in clinical development as monotherapy and in combination with TNO155, with both strategies showing antitumor activity in patients with KRASG12C-mutated tumors. Significance: JDQ443 is a structurally novel covalent KRASG12C inhibitor with a unique binding mode that demonstrates potent and selective antitumor activity in cell lines and in vivo models. In preclinical models and patients with KRASG12C-mutated malignancies, JDQ443 shows potent antitumor activity as monotherapy and in combination with the SHP2 inhibitor TNO155. See related video: https://vimeo.com/720726054 This article is highlighted in the In This Issue feature, p. 1397
Overview
CoChat Summary
TL;DR
JDQ443 is a structurally novel, orally bioavailable covalent inhibitor of GDP-bound KRASG12C with a distinct switch II pocket binding mode, potent mutant-selective preclinical activity, and early clinical responses alone and with the SHP2 inhibitor TNO155. Preclinical efficacy is driven by daily AUC and sustained KRASG12C target occupancy, and combinations improve single-agent activity in NSCLC and colorectal cancer models.
Key findings
- JDQ443 covalently and selectively binds GDP-bound KRASG12C: biochemical kinact/Ki was 141 (5.1) [34], with low reversible binding affinity to RAS WT paralogs in the GDP-bound state and all GMPNP-bound affinities >200; cellular cRAF recruitment IC50 was 0.012 (0.0008) for KRASG12C versus >1 for KRASWT, NRASWT, and HRASWT (Table 1).
- JDQ443 selectively inhibited KRASG12C-mutated cell lines in a 242-line CCLE panel (17 KRASG12C-mutant, 225 non–G12C-mutant) and showed proteome-wide selectivity by competing >2-fold with the KRAS cysteine-12 peptide among >11,500 cysteine-containing peptides, with eight additional cysteine residues on six proteins showing similar competition.
- In CDX models, JDQ443 produced dose-dependent antitumor activity ranging from regression (MIA PaCa-2, LU99) to stasis (HCC44, NCI-H2122) to moderate inhibition (NCI-H2030, KYSE410), with no growth inhibition in a KRASG12V-mutated NCI-H441 model; efficacy correlated with daily AUC and KRASG12C target occupancy rather than Cmax or time over threshold.
- JDQ443 plus TNO155 improved single-agent activity; in LU99 and HCC44, JDQ443 30 mg/kg q.d. plus TNO155 7.5 mg/kg b.i.d. achieved the same response as single-agent JDQ443 100 mg/kg q.d., and in KYSE410 the combination achieved tumor stasis. Two clinical cases showed RECIST 1.1 partial responses: −30.4% on JDQ443 monotherapy 200 mg b.i.d. in KRASG12C-mutated NSCLC, and −44.2% on JDQ443 200 mg q.d. plus TNO155 20 mg q.d. in KRASG12C-mutated duodenal papillary cancer.
Methods
- Discovery used structure-based de novo design, SAR optimization, cocrystal structures, and an MS-based screen of 3,315 molecules yielding 107 confirmed hits with single KRASG12C target modification and >50% modification after 2 hours at 50 μmol/L; glutathione reactivity was used to assess promiscuous cysteine reactivity.
- Preclinical characterization included biochemical covalent competition and surface plasmon resonance assays, NanoBiT KRAS:cRAF recruitment, pERK and proliferation assays, CCLE cell-line profiling, LC/MS tandem mass tag cysteine proteomics, Ba/F3 KRASG12C second-site mutants, CDX and PDX mouse studies, PK/PD modeling, continuous intravenous infusion, and 1 × 1 × 1 mouse clinical trial PDX panels.
- Clinical data came from the phase Ib/II KontRASt-01 trial (NCT04699188), an open-label, multicenter dose-escalation and -expansion study of JDQ443 alone or with TNO155 and/or tislelizumab in adults with KRASG12C-mutated solid tumors; two illustrative cases are reported.
Limitations
- The paper states that in the PDX panels, sample size did not enable conclusive correlations between genetic comutations and efficacy.
- The paper states that phase I studies present a high risk of patient reidentification, so individual patient results cannot be shared, and some clinical data are subject to contractual or consent restrictions.
- Evident from the text: clinical activity is illustrated by only two cases from an ongoing trial, with no mature safety, efficacy, or randomized comparison data; preclinical efficacy relies on mouse CDX/PDX models, and resistance testing covers selected KRASG12C second-site mutants rather than the full diversity of clinical resistance.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures
![Figure 1. Design of JDQ443 and its binding mode to KRASG12C. A, Scheme of the design concept to maintain the indazole and the phenyl acrylamide pharmacophores and design a scaffold to link them. Several scaffolds were evaluated in silico and the best group (dimethyl pyrazole) selected for synthesis [3] and further optimized to give JDQ443 ([5]; see Supplementary Table S1). B, Crystal structure of JDQ443 monomer 1 in complex with KRASG12C. H-bonds are shown as yellow dotted lines. The indazole moiety forms H-bond interactions with the side chain of D69 and the backbone amide donor of S65 as well as fills the hydrophobic region delimited by V103, I100, M72, and Q99 (Cα and Cβ). The pyrazole is positioned at ∼60° to the indazole fragment with the methyl pointing toward R68, T58, M72, and V9. In addition, it forms edge-to-face interactions with Y96. The spirocyclic group is a rigid linker optimally orienting the acrylamide toward C12 and the amide carbonyl to form hydrogen bond interactions with the side chain of K16 and water-mediated interaction to the Mg2+ ion and the beta phosphoryl group of GDP. The methyl–indazole moiety is almost planar to the pyrazole, and it is sandwiched between the switch II and the Q99 side chain (black dotted lines). Major differences between the two JDQ443 monomers are the conformation of H95 (pointing toward the ligand in monomer 2; Supplementary Fig. S3) and the interactions of the methyl–indazole moiety.](https://figures.cochat.ai/paper-figures/69b86444b76d4318bc142d35abbeee11/discovery-preclinical-characterization-and-early-clinical-activity-of-jdq443-a-figure-1.jpg)

![Figure 3. JDQ443 displays antitumor activity across a range of cell-derived, KRASG12C-dependent mouse tumor models, with efficacy driven by daily AUC. A, Aggregated best tumor growth inhibition in six KRASG12C tumor models. JDQ443 efficacy was evaluated after oral dosing of 10, 30, and 100 mg/kg/day in six human KRASG12C-mutant CDX models in mice. NSCLC cell line models are depicted in red, whereas PDAC (MIA Paca-2) and esophageal (KYSE410) cancer cell line models are shown in blue. Data are means from 2–11 independent in vivo studies. %Regr. is percentage tumor volume regression [–(Δtreated/treated at baseline) × 100], and %T/C is percentage tumor volume growth ratio [(Δtreated/Δcontrol) × 100]. B–G, CDX-bearing mice with KRASG12C-mutated (C–G) and non–G12C-mutated (NCI-441, KRASG12V; B) tumors were treated orally (p.o.) with JDQ443 at the indicated doses and schedules. G, LU99 tumor–bearing mice were treated with JDQ443 by continuous intravenous infusion using a programmable microinfusion pump. H and I, Simulated population-PK/PD metrics of daily AUC of JDQ443 in mouse blood (H) and average free KRASG12C levels in tumor at steady state (I) are correlated with the observed efficacy in LU99 (%T/C or % regression). Points correspond to the mean and the error bars to ± 1 SD of the simulated PK/PD metrics based on 100 simulations and observed efficacy metrics. *, P < 0.05 versus vehicle; #, P < 0.05 versus each other, by one-way ANOVA.](https://figures.cochat.ai/paper-figures/ba47da11a56e4199845bb57b3b285bb0/discovery-preclinical-characterization-and-early-clinical-activity-of-jdq443-a-figure-3.jpg)



Verification
Claims the paper makes
9 Valid · 1 Not valid · 13 Not checked · 98 Own results and interpretations
Every source the paper cites for this claim was checked and supports it.
In the paper
“was recently found to be targetable by small-molecule inhibitors (8, 9).”
§ Discovery, Preclinical Characterization, and Early Clinical Activity of JDQ443, a Structurally Novel, Potent, and Selective Covalent Oral Inhibitor of KRASG12C > INTRODUCTION
What the sources say
- Supportedcites [8] Lim SM, Westover KD, Ficarro SB, Harrison RA, Choi HG, Pacold ME,. Therapeutic targeting of oncogenic K-Ras by a covalent catalytic site inhibitor. Angew Chem Int Ed Engl 2014; 53: 199– 204. 24259466 PMC3914205 source
The Abstract of our copy states that SML-8-73-1 (a GDP analogue bearing an electrophilic chloroacetamide) and its prodrug SML-10-70-1 are 'selective, direct-acting covalent inhibitors of the K-Ras G12C mutant relative to wild-type Ras' and that these 'first-in-class covalent K-Ras inhibitors demonstrate that irreversible targeting of the K-Ras guanine-nucleotide binding site is potentially a viable therapeutic strategy'. A Results passage (p. ~4, EC50 6.6 nM labeling of K-Ras G12C) and the cellular target-engagement experiment in H358 cells further show the mutant is engaged by a small molecule in a cellular context. This directly supports the attributed point that KRAS G12C is targetable by small-molecule inhibitors (the paper's own caveats about cell permeability do not negate targetability). (LLM, conf=0.90)
- Supportedcites [9] Ostrem JM, Peters U, Sos ML, Wells JA, Shokat KM. K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions. Nature 2013; 503: 548– 51. 24256730 PMC4274051 source
The Abstract of Ostrem et al. (2013) states 'Here we report the development of small molecules that irreversibly bind to a common oncogenic mutant, K-Ras(G12C)', relying on the mutant cysteine and sparing wild-type protein, and concludes that the new allosteric site (S-IIP) 'is targetable in a mutant-specific manner'. The Discussion confirms identification of the S-IIP pocket and 'irreversible, mutant-specific inhibitors of Ras function', with cellular data in G12C-containing lung cancer cell lines (compound 12, EC50 0.32 microM in H1792) showing allele-specific impairment. The claim as paraphrased is fully covered by our copy. (LLM, conf=0.92)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“the compound ARS-1620 (17), which showed the first in vivo validation in patient-derived mouse models of KRASG12C-mutated NSCLC and PDAC.”
§ Discovery, Preclinical Characterization, and Early Clinical Activity of JDQ443, a Structurally Novel, Potent, and Selective Covalent Oral Inhibitor of KRASG12C > INTRODUCTION
What the sources say
- Supportedcites [17] Janes MR, Zhang J, Li LS, Hansen R, Peters U, Guo X,. Targeting KRAS mutant cancers with a covalent G12C-specific inhibitor. Cell 2018; 172: 578– 89. 29373830 source
The Results describe ARS-1620 testing in patient-derived mouse xenografts comprising three KRAS p.G12C NSCLC models and one pancreatic adenocarcinoma model, and report tumor inhibition and regression in the p.G12C models. The Discussion calls the study the first in vivo evidence for this KRASG12C-targeted approach. Page numbers are unavailable in our copy. (LLM, conf=0.93)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“JDQ443 antiproliferative activity was assessed by a high-throughput cell viability assay in a large panel of KRASG12C-mutated (N = 17) and non–G12C-mutated (N = 225) cell lines from the Cancer Cell Line Encyclopedia (29). JDQ443 demonstrated potent antiproliferative activity selectively toward the KRASG12C-mutated lines (Fig. 2A and B).”
§ Discovery, Preclinical Characterization, and Early Clinical Activity of JDQ443, a Structurally Novel, Potent, and Selective Covalent Oral Inhibitor of KRASG12C > RESULTS > JDQ443 Potently Inhibits KRASG12C Cellular Signaling and Proliferation in a Mutant-Selective Manner
What the sources say
- Supportedcites [29] Barretina J, Caponigro G, Stransky N, Venkatesan K, Margolin AA, Kim S,. The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature 2012; 483: 603– 7. 22460905 PMC3320027 source
The citation is attached to the provenance of the cell-line panel ('cell lines from the Cancer Cell Line Encyclopedia (29)'), not to the JDQ443 selectivity result, which the citing authors report as their own finding (Fig. 2A, B). Our copy identifies itself as that resource: the Abstract (p. 1) describes CCLE as 'a compilation of gene expression, chromosomal copy number, and massively parallel sequencing data from 947 human cancer cell lines' with 'pharmacologic profiles for 24 anticancer drugs across 479 of the lines', and the Methods Summary confirms mutation annotation by targeted sequencing of >1,600 genes plus OncoMap genotyping of recurrent mutations in 33 cancer genes (KRAS among them, per the Fig. 2c/Supplementary Tables 8-9 discussion). The specific N = 17 KRASG12C and N = 225 non-G12C counts are the citing authors' subset definitions and are not attributed to this source, so no qualifier is missing from what is credited here. (LLM, conf=0.85)
boostedstates a causen = 17- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Previous studies demonstrating an elevated pool of GDP-bound KRASG12C under SHP2 inhibition (38, 48) provide a rationale for combining JDQ443 and the SHP2 inhibitor TNO155.”
§ Discovery, Preclinical Characterization, and Early Clinical Activity of JDQ443, a Structurally Novel, Potent, and Selective Covalent Oral Inhibitor of KRASG12C > DISCUSSION
What the sources say
- Partly supportedcites [38] Ryan MB, Fece de la Cruz F, Phat S, Myers DT, Wong E, Shahzade HA,. Vertical pathway inhibition overcomes adaptive feedback resistance to KRAS(G12C) inhibition. Clin Cancer Res 2020; 26: 1633– 43. 31776128 PMC7124991 sourceExperimental — accuracy not yet measured
The Results section reports reduced KRAS-GTP with SHP2 inhibition and stronger suppression when SHP099 is combined with ARS-1620. The Discussion says SHP2 inhibition reduces cycling to the active GTP-bound state and supports combining SHP2 and KRASG12C inhibitors. The paper does not directly demonstrate an elevated GDP-bound KRASG12C pool or test JDQ443 with TNO155. (LLM, conf=0.82)
- Supportedcites [48] Fedele C, Li S, Teng KW, Foster CJR, Peng D, Ran H,. SHP2 inhibition diminishes KRASG12C cycling and promotes tumor microenvironment remodeling. J Exp Med 2021; 218: e20201414. 33045063 PMC7549316 source
The Introduction explains that inhibiting exchange could increase occupancy of KRASG12C-GDP, the form accessible to G12C inhibitors. In the Results (section “SHP2 inhibition enhances KRASG12C inhibitor effects in PDAC and NSCLC cell lines”), SHP2 inhibition accelerated inhibitor binding to KRASG12C, supporting that mechanistic rationale. The cited experiments used SHP099 and ARS1620; the choice of JDQ443 and TNO155 is the citing authors’ proposed application. (LLM, conf=0.88)
boostedstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Second-site mutations within the SWIIP show distinct sensitivity to adagrasib versus sotorasib depending on the binding mode of the inhibitor (42).”
§ Discovery, Preclinical Characterization, and Early Clinical Activity of JDQ443, a Structurally Novel, Potent, and Selective Covalent Oral Inhibitor of KRASG12C > DISCUSSION
What the sources say
- Partly supportedcites [42] Koga T, Suda K, Fujino T, Ohara S, Hamada A, Nishino M,. KRAS secondary mutations that confer acquired resistance to KRAS G12C inhibitors, sotorasib and adagrasib, and overcoming strategies: insights from in vitro experiments. J Thorac Oncol 2021; 16: 1321– 32. 33971321 sourceExperimental — accuracy not yet measured
The Cross Resistance results (p. 6) show that several secondary KRAS mutations have different sensitivities to adagrasib and sotorasib. The Discussion (p. 9) places several mutation sites around the drug-binding pocket and suggests they may impair binding, but does not establish that differences in inhibitor binding mode cause the distinct sensitivities. (LLM, conf=0.83)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
48 more claims
Create a free account to see all 121 claims and to verify the 30 references still open.
- Probably not a substantial claim. 17
- It may state two separate claims as one. 57
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Clinical trials of multiple KRASG12C inhibitors have shown promising efficacy in advanced, previously treated non–small cell lung cancer (NSCLC), leading to United States Food and Drug Administration (FDA) accelerated approval of two of these therapies (adagrasib and sotorasib) and many others being investigated in this setting (9–17).”
From Mechanisms of Resistance to Oncogenic KRAS Inhibition in Pancreatic Cancer (2024) · cites this paper as [17]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“In order to overcome the resistance of other KRASG12C inhibitors, JDQ-443 covalently binds to the “Switch II pocket” of KRASG12C and irreversibly locks it into an inactive GDP binding state.”
From Recent advances in targeting the “undruggable” proteins: from drug discovery to clinical trials (2023) · cites this paper as [73]
The cited source says what the claim attributes to it.
In the citing paper
“Furthermore, JDQ-443 in conjunction with the SHP 2 inhibitor TNO-155 has demonstrated a synergistic effect in preclinical animal models, resulting in improved outcomes at lower doses.73”
From Recent advances in targeting the “undruggable” proteins: from drug discovery to clinical trials (2023) · cites this paper as [73]
In the citing paper
“For example, combinations of G12Ci and SHP2 inhibitors (SHP2i) such TNO155 (14) and RMC-4550 (15) have been validated pre-clinically and are now being explored in the clinic (NCT04699188, NCT05480865).”
From Genome-Wide CRISPR Screens Identify Multiple Synthetic Lethal Targets That Enhance KRASG12C Inhibitor Efficacy (2023) · cites this paper as [14]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Discovery, Preclinical Characterization, and Early Clinical Activity of JDQ443, a Structurally Novel, Potent, and Selective Covalent Oral Inhibitor of KRASG12C > RESULTS > JDQ443 Potently Inhibits KRASG12C Cellular Signaling and Proliferation in a Mutant-Selective Manner
“JDQ443 covalently and selectively binds and inhibits GDP-bound KRASG12C with low reversible binding affinity to the RAS switch II pocket, and also inhibits proliferation of KRASG12C-mutated and KRAS G12C/H95, G12C/R68S, and G12C/Y96 double-mutant cell lines”
§ Discovery, Preclinical Characterization, and Early Clinical Activity of JDQ443, a Structurally Novel, Potent, and Selective Covalent Oral Inhibitor of KRASG12C > RESULTS > JDQ443 Potently Inhibits KRASG12C Cellular Signaling and Proliferation in a Mutant-Selective Manner
“whereas expression of G12C/R68S, G12C/Y96C, and G12C/Y96D double mutants conferred resistance to JDQ443.”
Citations
Cites
Cerami, E., Gao, J., Dogrusoz, U., Gross, B. E., Sumer, S. O., Aksoy, B. A., Jacobsen, A., Byrne, C. J., Heuer, M. L., Larsson, E., et al. (2012) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0095 · Cited by 17,455
New Guidelines to Evaluate the Response to Treatment in Solid Tumors
Therasse, P., Arbuck, S. G., Eisenhauer, E. A., Wanders, J., Kaplan, R. S., Rubinstein, L., Verweij, J., Van Glabbeke, M., van Oosterom, A. T., Christian, M. C., et al. (2000) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/92.3.205 · Cited by 15,660
Integrative Analysis of Complex Cancer Genomics and Clinical Profiles Using the cBioPortal
Gao, J., Aksoy, B. A., Dogrusoz, U., Dresdner, G., Gross, B., Sumer, S. O., Sun, Y., Jacobsen, A., Sinha, R., Larsson, E., et al. (2013) · Science Signaling · doi:10.1126/scisignal.2004088 · Cited by 15,160
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity
Barretina, J., Caponigro, G., Stransky, N., Venkatesan, K., Margolin, A. A., Kim, S., Wilson, C. J., Lehár, J., Kryukov, G. V., Sonkin, D., et al. (2012) · Nature · doi:10.1038/nature11003 · Cited by 7,950 · cited 3×
“In silico Optimization GDP-bound: • KRAS WT • KRAS G12C 0.012 (0.0008) • KRAS G12C 0.018 (0.003) • RAS WT MEK Q56P > 1 • KRAS G12C 0.063 (0.004) • RAS WT MEK Q56P > 1 In order to assess the breadth of mutant selectivity in a cellular setting, JDQ443 antiproliferative activity was assessed by a high-throughput cell via…”
InfluentialNext-generation characterization of the Cancer Cell Line Encyclopedia
Ghandi, M., Huang, F. W., Jané-Valbuena, J., Kryukov, G. V., Lo, C. C., McDonald, E. R., Barretina, J., Gelfand, E. T., Bielski, C. M., Li, H., et al. (2019) · Nature · doi:10.1038/s41586-019-1186-3 · Cited by 3,394
A Chromatin-Mediated Reversible Drug-Tolerant State in Cancer Cell Subpopulations
Sharma, S. V., Lee, D. Y., Li, B., Quinlan, M. P., Takahashi, F., Maheswaran, S., McDermott, U., Azizian, N., Zou, L., Fischbach, M. A., et al. (2010) · Cell · doi:10.1016/j.cell.2010.02.027 · Cited by 2,770
K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions
Ostrem, J. M., Peters, U., Sos, M. L., Wells, J. A., & Shokat, K. M. (2013) · Nature · doi:10.1038/nature12796 · Cited by 2,557 · cited 3×
“…one common KRAS oncogenic variant—a glycine-to-cysteine sub-stitution at amino acid 12 (KRAS G12C ) that occurs in approximately 13% of lung adenocarcinomas, 4% of colon tumors, and smaller fractions of other cancers (7)—was recently found to be targetable by small-molecule inhibitors (8, 9).”
The Clinical KRAS(G12C) Inhibitor AMG 510 Drives Anti-Tumour Immunity
Canon, J., Rex, K., Saiki, A. Y., Mohr, C., Cooke, K., Bagal, D., Gaida, K., Holt, T., Knutson, C. G., Koppada, N., et al. (2019) · Nature · doi:10.1038/s41586-019-1694-1 · Cited by 2,277 · cited 1×
“18) and adagrasib (MRTX-849; ref.”
Drugging the undruggable RAS: Mission Possible?
Cox, A. D., Fesik, S. W., Kimmelman, A. C., Luo, J., & Der, C. J. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4389 · Cited by 1,997 · cited 1×
“…nucleotides, an apparent absence of targetable allosteric sites, and the clinical failure of attempts to target other critical aspects of KRAS functioning such as KRAS membrane attachment (6) or inhibition of downstream signaling in the absence of direct selective inhibition of the driver oncogene.”
RAS Proteins and Their Regulators in Human Disease
Simanshu, D. K., Nissley, D. V., & McCormick, F. (2017) · Cell · doi:10.1016/j.cell.2017.06.009 · Cited by 1,943 · cited 1×
“This resulted in replacement of the aniline linker by a spirocyclic azetidine moiety, as represented with [4] (Supplementary Table S1).”
Research works printed but not linked: 1
- Weiss J, Yaeger RD, Johnson ML, Spira A, Klempner SJ, Barve MA,. KRYSTAL-1: adagrasib (MRTX849) as monotherapy or combined with cetuximab (Cetux) in patients (Pts) with colorectal cancer (CRC) harboring a KRASG12C mutation. Ann Oncol 2021;32(suppl_5):S1283–S1346. Abstract nr LBA6.
Cited by
Recent advances in targeting the “undruggable” proteins: from drug discovery to clinical trials
Xie, X., Yu, T., Li, X., Zhang, N., Foster, L. J., Peng, C., Huang, W., & He, G. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01589-z · Cited by 396
Mechanisms of Resistance to Oncogenic KRAS Inhibition in Pancreatic Cancer
Dilly, J., Hoffman, M. T., Abbassi, L., Li, Z., Paradiso, F., Parent, B. D., Hennessey, C. J., Jordan, A. C., Morgado, M., Dasgupta, S., et al. (2024) · Cancer Discovery · doi:10.1158/2159-8290.cd-24-0177 · Cited by 308
“…have shown promising efficacy in advanced, previously treated non–small cell lung cancer (NSCLC), leading to United States Food and Drug Administration (FDA) accelerated approval of two of these therapies (adagrasib and sotorasib) and many others being investigated in this setting (9–17).”
BackgroundChemical remodeling of a cellular chaperone to target the active state of mutant KRAS
Schulze, C. J., Seamon, K. J., Zhao, Y., Yang, Y. C., Cregg, J., Kim, D., Tomlinson, A., Choy, T. J., Wang, Z., Sang, B., et al. (2023) · Science · doi:10.1126/science.adg9652 · Cited by 264
Comutations and KRASG12C Inhibitor Efficacy in Advanced NSCLC
Negrao, M. V., Araujo, H. A., Lamberti, G., Cooper, A. J., Akhave, N. S., Zhou, T., Delasos, L., Hicks, J. K., Aldea, M., Minuti, G., et al. (2023) · Cancer Discovery · doi:10.1158/2159-8290.cd-22-1420 · Cited by 203
Small molecule inhibitors targeting the cancers
Liu, G., Chen, T., Zhang, X., Ma, X., & Shi, H. (2022) · MedComm · doi:10.1002/mco2.181 · Cited by 184
Chapeau, E. A., Sansregret, L., Galli, G. G., Chène, P., Wartmann, M., Mourikis, T. P., Jaaks, P., Baltschukat, S., Barbosa, I. A. M., Bauer, D., et al. (2024) · Nature Cancer · doi:10.1038/s43018-024-00754-9 · Cited by 159
“Some blots were partially shown in a previous report 48 .”
Self-citationMukhopadhyay, S., Huang, H.-Y., Lin, Z., Ranieri, M., Li, S., Sahu, S., Liu, Y., Ban, Y., Guidry, K., Hu, H., et al. (2023) · Cancer Research · doi:10.1158/0008-5472.can-23-2729 · Cited by 105
Lorthiois, E., Gerspacher, M., Beyer, K. S., Vaupel, A., Leblanc, C., Stringer, R., Weiss, A., Wilcken, R., Guthy, D. A., Lingel, A., et al. (2022) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.2c01438 · Cited by 110
Self-citationKRAS G12C inhibitor combination therapies: current evidence and challenge
Miyashita, H., Kato, S., & Hong, D. S. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1380584 · Cited by 85
“Multiple in vitro and in vivo studies demonstrated enhanced activity of KRAS G12C inhibitors combined with CDK4/6 inhibitors (62, 65).”
BackgroundMYC and KRAS cooperation: from historical challenges to therapeutic opportunities in cancer
Casacuberta‐Serra, S., González-Larreategui, Í., Capitán-Leo, D., & Soucek, L. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01907-z · Cited by 100
The next-generation KRAS inhibitors…What comes after sotorasib and adagrasib?
Oya, Y., Imaizumi, K., & Mitsudomi, T. (2024) · Lung Cancer · doi:10.1016/j.lungcan.2024.107886 · Cited by 65
Development of covalent inhibitors: Principle, design, and application in cancer
Zheng, L., Li, Y., Wu, D., Xiao, H., Zheng, S., Wang, G., & Sun, Q. (2023) · MedComm – Oncology · doi:10.1002/mog2.56 · Cited by 71
Precision oncology provides opportunities for targeting KRAS-inhibitor resistance
Sattler, M., Mohanty, A., Kulkarni, P., & Salgia, R. (2023) · Trends in Cancer · doi:10.1016/j.trecan.2022.10.001 · Cited by 54
Attili, I., Corvaja, C., Spitaleri, G., Signore, E. D., Aliaga, P. T., Passaro, A., & de Marinis, F. (2023) · Cancers · doi:10.3390/cancers15205079 · Cited by 58
“…mechanisms observed with other KRAS G12C inhibitors since it acts through a novel binding mechanism that forms novel interactions with KRAS under the switch II pocket, irreversibly trapping KRAS in the inactive, GDP-bound state reaching the residue C12 without interfering with residue H95 [125].”
BackgroundKras oncogene ablation prevents resistance in advanced lung adenocarcinomas
Salmón, M., Álvarez-Díaz, R., Fustero-Torre, C., Brehey, O., Lechuga, C. G., Sanclemente, M., Fernández-García, F., López-García, A., Martín-Guijarro, M. C., Rodríguez-Perales, S., et al. (2023) · Journal of Clinical Investigation · doi:10.1172/jci164413 · Cited by 52
“Other KRAS G12C inhibitors, such as JDQ443, characterized by a novel binding mode, have been described as well as new compounds that inhibit KRAS noncova-lently and independently of its GDP/guanosine triphosphate (GTP) state (8, 9).”
Emerging Targets in Non-Small Cell Lung Cancer
Liu, L., Soler, J., Reckamp, K. L., & Sankar, K. N. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms251810046 · Cited by 64
“Preclinical investigation of opnurasib (JDQ443) showed potent and selective anti-tumor activity in KRAS G12C cell lines and comparable efficacy to sotorasib [31].”
BackgroundAnnual review of KRAS inhibitors in 2022
Wang, H., Chi, L., Yu, F., Dai, H., Gao, C., Si, X., Wang, Z., Liu, L., Zheng, J., Shan, L., et al. (2023) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2023.115124 · Cited by 57
Targeting KRAS G12C Mutation in Colorectal Cancer, A Review: New Arrows in the Quiver
Ros, J., Vaghi, C., Baraibar, I., Gonzalez, N. S., Rodríguez-Castells, M., García, A., Alcaráz, A., Salvà, F., Tabernero, J. M., & Élez, E. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25063304 · Cited by 62
“Both these strategies are already under investigation [41,47,48,50].”
BackgroundThummalapalli, R., Bernstein, E., Herzberg, B. O., Li, B. T., Iqbal, A. N., Preeshagul, I. R., Santini, F. C., Eng, J., Ladanyi, M., Yang, S., et al. (2023) · JCO Precision Oncology · doi:10.1200/po.23.00030 · Cited by 61
“12 Despite the activity of sotorasib demonstrated in clinical trials, there are currently no real-world data describing clinical activity and toxicities observed among patients treated with sotorasib as part of routine care to help guide adoption in the clinic.”
BackgroundFrom bench to bedside: current development and emerging trend of KRAS-targeted therapy
Chen, Y., Liu, Q.-P., Xie, H., & Ding, J. (2023) · Acta Pharmacologica Sinica · doi:10.1038/s41401-023-01194-4 · Cited by 47
“JDQ443 selectively inhibited KRAS G12C -mutated tumor cells in vitro and displayed antitumor effects in multiple KRAS G12C - dependent CDX and PDX models, synergistically with SHP2 inhibitors [6].”
Resistance to KRAS G12C Inhibition in Non-small Cell Lung Cancer
Federico, A. D., Ricciotti, I., Favorito, V., Michelina, S. V., Scaparone, P., Metro, G., Giglio, A. D., Pecci, F., Lamberti, G., Ambrogio, C., et al. (2023) · Current Oncology Reports · doi:10.1007/s11912-023-01436-y · Cited by 47
The Therapeutic Landscape for KRAS-Mutated Colorectal Cancers
Tria, S. M., Burge, M. E., & Whitehall, V. L. J. (2023) · Cancers · doi:10.3390/cancers15082375 · Cited by 38
“Cancers 2023, 15, 2375 19 of 25 Both Adagrasib and Sotorasib have performed favorably in the clinic.”
InfluentialD‐1553: A novel KRASG12C inhibitor with potent and selective cellular and in vivo antitumor activity
Shi, Z., Weng, J., Niu, H., Yang, H., Liu, R., Weng, Y., Zhu, Q., Zhang, Y., Tao, L., Wang, Z., et al. (2023) · Cancer Science · doi:10.1111/cas.15829 · Cited by 38
Kettle, J. G., Bagal, S. K., Barratt, D. G., Bodnarchuk, M. S., Boyd, S., Braybrooke, E. L., Breed, J., Cassar, D. J., Cosulich, S. C., Davies, M., et al. (2023) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.3c00746 · Cited by 40
Zhang, J., Lim, S. M., Yu, M. R., Chen, C., Wang, J., Wang, W., Rui, H., Lu, J., Lü, S., Mok, T. S. K., et al. (2024) · Cancer Discovery · doi:10.1158/2159-8290.cd-24-0006 · Cited by 42
Feng, J., Xiao, X., Xia, X., Min, J., Tang, W., Shi, X., Xu, K., Zhou, G., Li, K., Shen, P., et al. (2025) · Cancer Cell · doi:10.1016/j.ccell.2025.07.006 · Cited by 46
Self-citationThe current landscape of using direct inhibitors to target KRASG12C-mutated NSCLC
Batrash, F., Kutmah, M., & Zhang, J. (2023) · Experimental Hematology and Oncology · doi:10.1186/s40164-023-00453-8 · Cited by 43
“…advanced solid tumors (NCT04699188; Table 3) where together they showed partial response in a patient with NSCLC who had previously received chemotherapy and immunotherapy (carboplatin/pemetrexed/pembrolizumab, docetaxel, tegafur–gimeracil–oteracil, and carboplatin/ paclitaxel/atezolizumab) [106].”
BackgroundRAS degraders: The new frontier for RAS-driven cancers
Escher, T. E., & Satchell, K. J. F. (2023) · Molecular Therapy · doi:10.1016/j.ymthe.2023.03.017 · Cited by 42
Prognostic and therapeutic impact of the KRAS G12C mutation in colorectal cancer
Qunaj, L., May, M. S., Neugut, A. I., & Herzberg, B. O. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1252516 · Cited by 48
“As a result of its H95-independent mechanism, it appears to maintain activity even among tumors with G12C/H95 double KRAS mutations, which might help mitigate some acquired resistance (47).”
BackgroundYamane, D., Tetsukawa, R., Zenmyo, N., Tabata, K., Yoshida, Y., Matsunaga, N., Shindo, N., & Ojida, A. (2023) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.3c00737 · Cited by 36
Structural insights into small-molecule KRAS inhibitors for targeting KRAS mutant cancers
Pandey, D., Chauhan, S. C., Kashyap, V. K., & Roy, K. K. (2024) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2024.116771 · Cited by 32
Recent progress in targeting KRAS mutant cancers with covalent G12C-specific inhibitors
Rathod, L. S., Dabhade, P. S., & Mokale, S. N. (2023) · Drug Discovery Today · doi:10.1016/j.drudis.2023.103557 · Cited by 33
Prahallad, A., Weiss, A., Voshol, H., Kerr, G., Sprouffske, K., Yuan, T., Ruddy, D., Meistertzheim, M., Kazic-Legueux, M., Kottarathil, T., et al. (2023) · Cancer Research · doi:10.1158/0008-5472.can-23-1127 · Cited by 30
“Alpelisib (a PI3K a i) and ribociclib (a CDK4/6i) augment JDQ443 antitumor activity in patient-derived mouse xenografts of KRAS G12C -mutant NSCLC and colorectal tumors (20).”
BackgroundMethodInfluentialSelf-citationNegrao, M. V., Paula, A. G., Molkentine, D. P., Hover, L. D., Nilsson, M. B., Vokes, N. I., Engstrom, L. D., Calinisan, A., Briere, D. M., Waters, L. M., et al. (2025) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-24-2310 · Cited by 41
Covalent hits and where to find them
Lucas, S. C. C., Blackwell, J. H., Hewitt, S. H., Semple, H., Whitehurst, B. C., & Xu, H. (2024) · SLAS DISCOVERY · doi:10.1016/j.slasd.2024.01.003 · Cited by 32
Wang, Y., Yao, M., Li, C., Yang, K., Qin, X., Xu, L., Shi, S., Yu, C., Meng, X., & Xie, C. (2023) · Experimental Hematology & Oncology · doi:10.1186/s40164-023-00466-3 · Cited by 26
“Moreover, Volasertib significantly suppressed cell proliferation of Ba/F3 cells expressing KRAS G12C or KRAS G12C second-site mutants, which have been reported to confer acquired resistance to KRAS G12C i [5, 36] (Fig.”
BackgroundDynamic conformational equilibria in the active states of KRAS and NRAS
Rennella, E., Henry, C., Dickson, C. J., Georgescauld, F., Wales, T. E., Erdmann, D., Cotesta, S., Maira, S.-M., Sedrani, R. C., Brachmann, S. M., et al. (2024) · RSC Chemical Biology · doi:10.1039/d4cb00233d · Cited by 25
Self-citationEmerging Targeted Therapies in Non-Small-Cell Lung Cancer (NSCLC)
Mina, S. A., Shanshal, M., Leventakos, K., & Parikh, K. (2025) · Cancers · doi:10.3390/cancers17030353 · Cited by 35
“In preclinical models, it potently inhibited KRAS G12C cellular signaling and proliferation in a mutant-selective manner and demonstrated dose-dependent antitumor activity [22].”
Huang, D. S., Manoni, F., Sun, Z., Liu, R., Allen, J. R., Banerjee, A., Cee, V. J., Eshon, J., Frohn, M. J., Kaller, M. R., et al. (2025) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.4c03071 · Cited by 24
Direct GDP-KRAS G12C inhibitors and mechanisms of resistance: the tip of the iceberg
Rosen, J. C., Sacher, A. G., & Tsao, M. (2023) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359231160141 · Cited by 24
Sharma, A. K., Pei, J., Yang, Y., Dyba, M. D., Smith, B. D., Rabara, D., Larsen, E. K., Lightstone, F. C., Esposito, D., Stephen, A. G., et al. (2024) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2024.105650 · Cited by 26
Alexander, P., Chan, A. H., Rabara, D., Swain, M., Larsen, E. K., Dyba, M. D., Chertov, O., Ashraf, M., Champagne, A., Lin, K. Y., et al. (2025) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2025.110331 · Cited by 27
Covalent inhibitors: An ambitious approach for the discovery of newer oncotherapeutics
Cheke, R. S., & Kharkar, P. S. (2023) · Drug Development Research · doi:10.1002/ddr.22132 · Cited by 26
KRAS-Driven Tumorigenesis and KRAS-Driven Therapy in Pancreatic Adenocarcinoma
Than, M. T., O’Hara, M. H., Stanger, B. Z., & Reiss, K. A. (2024) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-23-0519 · Cited by 23
KRAS mutated NSCLC: past, present, and future directions in a rapidly evolving landscape
Frisch, A., Martin, E., Kim, S. Y., Riess, J. W., Sen, T., & Karim, N. A. (2025) · The Oncologist · doi:10.1093/oncolo/oyaf153 · Cited by 27
Recent advances in the development of inhibitors targeting KRAS-G12C and its related pathways
Zhao, D., Liu, Y., Yi, F., Zhao, X., & Lu, K. (2023) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2023.115698 · Cited by 21
Experimental models for cancer brain metastasis
Liu, Z., Dong, S., Liu, M., Liu, Y., Ye, Z., Zeng, J., & Yao, M. (2023) · Cancer Pathogenesis and Therapy · doi:10.1016/j.cpt.2023.10.005 · Cited by 22
“56”
Targeting RAF dimers in RAS mutant tumors: From biology to clinic
Yin, H., Tang, Q., Xia, H., & Bi, F. (2024) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2024.02.018 · Cited by 21
Attili, I., Corvaja, C., Aliaga, P. T., Signore, E. D., Spitaleri, G., Passaro, A., & de Marinis, F. (2025) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2025.102957 · Cited by 20
Tang, N., Li, J., Gu, A., Li, M., & Liu, Y. (2025) · Molecular Biomedicine · doi:10.1186/s43556-025-00330-2 · Cited by 21
Zhong, J., Zhao, J., Duan, J., Fang, J., Fei, K., Li, X., Chen, J., Wang, Z., Chu, Q., Yu, Y., et al. (2025) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(25)00258-9 · Cited by 19
An updated overview of K-RAS G12C inhibitors in advanced stage non-small cell lung cancer
Tenekeci, A. K., Unal, A. A., Ceylan, F., & Sendur, M. A. N. (2024) · Future Oncology · doi:10.1080/14796694.2024.2407280 · Cited by 19
Advances in Targeted Therapy for Non-Small-Cell Lung Cancer: Current Progress and Future Directions
Peshin, S., Takrori, E., Yazji, J. H., Haque, J., Dharia, A. A., Mithani, M. S., Anum, F., Asfeen, U. Z., Couch, J. K., Donovan, M., et al. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms262311517 · Cited by 17
“Preclinical studies have shown mutant-selective, dose-dependent inhibition of tumor growth [128].”
Lu, X., Yu, R., Li, Z., Yang, M., Dai, J., & Liu, M. (2023) · Cancer Letters · doi:10.1016/j.canlet.2023.216517 · Cited by 14
Hajjo, R., Sabbah, D. A., Bardaweel, S. K., & Zhong, H. A. (2024) · Expert Opinion on Therapeutic Patents · doi:10.1080/13543776.2024.2327307 · Cited by 17
“Opnurasib (NVP-JDQ-443, 23 ) is an oral, covalent, and selective MUT G12C KRAS inhibitor [134,135].”
BackgroundAdvances in Novel Targeted Therapies for Pancreatic Adenocarcinoma
Hoang, T. A., & Tsang, E. S. (2025) · Journal of Gastrointestinal Cancer · doi:10.1007/s12029-024-01149-w · Cited by 18
“Preclinical studies have shown anti-tumor activity in combining KRAS G12C and CDK4/6 inhibitors, with ongoing clinical trials exploring this approach (NCT05178888, NCT04185883, NCT04956640, NCT05358249) [63, 64].”
Resistance to KRAS inhibition in advanced non-small cell lung cancer
Sreter, K. B., Catarata, M. J., von Laffert, M., & Frille, A. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1357898 · Cited by 12
Fernando, M. C., Craven, G. B., & Shokat, K. M. (2024) · Small GTPases · doi:10.1080/21541248.2025.2505441 · Cited by 13
“Three additional covalent KRAS G12C inhibitors currently undergoing clinical trials (olomorasib-LY3537982, opnurasib-JDQ443, and divarasib-GDC -6036) have also reported encouraging clinical outcomes [7,8].”
Assessment of KRASG12C inhibitors for colorectal cancer
Piazza, G. A., Chandrasekaran, P., Maxuitenko, Y. Y., & Budhwani, K. I. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1412435 · Cited by 11
Wang, Y., Xu, L., Ling, L., Yao, M., Shi, S., Yu, C., Li, Y., Shen, J., Jiang, H., & Xie, C. (2024) · Advanced Science · doi:10.1002/advs.202404926 · Cited by 14
Wang, P., Sun, X., He, X., Kang, D., Liu, X., Liu, D., Li, A., Yang, G., Lin, Y., Li, S., et al. (2025) · Cancer Research Communications · doi:10.1158/2767-9764.crc-25-0001 · Cited by 9
“Similarly, the KRAS G12C inhibitors sotorasib and JDQ443 had also displayed inhibitory effects on HRAS G12C and NRAS C12C, with the combination therapy of sotorasib and EGFR antibody pan-itumumab being successfully used to treat a patient with colorectal cancer with NRAS p.G12C mutation (33).”
Nucleic Acid-Based Approaches to Tackle KRAS Mutant Cancers
Kim, J. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms242316933 · Cited by 12
RAS and Other Molecular Targets in Pancreatic Cancer: The Next Wave Is Coming
Miller‐Phillips, L., & Collisson, E. A. (2023) · Current Treatment Options in Oncology · doi:10.1007/s11864-023-01096-x · Cited by 11
Rijmers, J., Retmana, I. A., Bui, V., Arguedas, D., Lebre, M. C., Sparidans, R. W., Beijnen, J. H., & Schinkel, A. H. (2024) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2024.116720 · Cited by 9
Leini, R., Kapp, J. N., Kopra, K., & Pantsar, T. (2025) · Scientific Reports · doi:10.1038/s41598-025-07532-2 · Cited by 10
Yu, J. X., Suh, J. M., Popova, K. D., Garcia, K., Joshi, T. V., Culbertson, B., Spinelli, J. B., Subramanyam, V., Lou, K., Charbonneau, T., et al. (2026) · Nature Cancer · doi:10.1038/s43018-026-01130-5 · Cited by 11
In Silico Evaluation of the Thr58-Associated Conserved Water with KRAS Switch-II Pocket Binders
Leini, R., & Pantsar, T. (2023) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.2c01479 · Cited by 9
Structure-Based Design and Evaluation of Reversible KRAS G13D Inhibitors
Nilewski, C., Labadie, S. S., Wei, B. Q., Malhotra, S., Do, S., Gazzard, L. J., Liu, L., Shao, C., Murray, J. M., Izrayelit, Y., et al. (2023) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.3c00478 · Cited by 9
Shi, J.-T., Hou, S.-J., Cheng, L., Zhang, H., Mu, H.-X., Wang, Q., Wang, Z., & Chen, S. (2024) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2024.107467 · Cited by 7
KRASG12C Inhibitors in Non-Small Cell Lung Cancer: A Review
Tang, M., Wu, Y., Bai, X., & Lü, Y. (2024) · OncoTargets and Therapy · doi:10.2147/ott.s473368 · Cited by 9
Identification and characterization of binders to a cryptic and functional pocket in KRAS
Beyer, K. S., Klein, J., Katz, S., Welker, P., Lanter, M., Guthy, D. A., Pollehn, K., Gluck-Gadé, A., Bleu, M., Desogus, J., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-65844-3 · Cited by 8
“To check whether KM12-AM would also bind RAS in cells, KRAS WT HEK293 cells stably expressing LgBit-KRAS G12D fusions 6 were transfected with expression vectors encoding HA-tagged and stabilized (Ser50mutated toAla) of either KM12-AM (referred asHA-KM12*) or KM12-AM-AA (referred as HA-KM12*-AA), a…”
Self-citationCovalent inhibitor design confers activity against both GDP- and GTP-bound forms of KRAS G12C
Condakes, M. L., Zhang, Z., Danahy, D. B., Moore, R. R., Lakkaraju, S. K., Zhuo, X., Amako, Y., Borzilleri, R. M., Balachander, S. B., Chourb, L. S., et al. (2026) · Nature Communications · doi:10.1038/s41467-026-69003-0 · Cited by 9
“5b) 33,34 .”
Discovery and Characterization of Divarasib (GDC-6036), a Potent Covalent Inhibitor of KRAS G12C
Endres, N., Do, S., Mroue, R. M., Terrett, J. A., Saabye, M., Oh, A., Hunsaker, T., Chan, E., (1471192), J. C. T., Nguyen, L. K., et al. (2026) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5c02272 · Cited by 12
Li, N., Liu, C., Zhang, W., & Rao, G. (2023) · Current Medicinal Chemistry · doi:10.2174/0109298673258913231019113814 · Cited by 8
Burska, A. N., Ilyassova, B., Dildabek, A., Khamijan, M., Бегимбетова, Д., Molnár, F., & Sarbassov, D. D. (2022) · Cells · doi:10.3390/cells11213454 · Cited by 9
“AMG 510 (generic name lumakras and sotorasib) was approved by the FDA in 2021 for treatment of a KRAS G12C mutation-positive non-small cell lung cancer (NSCLC).”
InfluentialDaley, B. R., Sealover, N. E., Sheffels, E., Hughes, J. M., Gerlach, D., Hofmann, M. H., Kostyrko, K., Mair, B., Linke, A. J., Beckley, Z., et al. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.12.07.570642 · Cited by 7
“…and acquired resistance limit their overall effectiveness (4,13-17, Studies show that inhibition of proximal RTK signaling using SHP2 (3,6,18,19,80) or SOS1 (51,53) inhibitors enhances G12Ci binding to mutated KRAS G12C and limits RTK-SOS-WT RAS signaling to overcome intrinsic G12Ci…”
Differential Response and Resistance to KRAS-Targeted Therapy
Liu, Z., Lenz, H., Yu, J., & Zhang, L. (2025) · Molecular Carcinogenesis · doi:10.1002/mc.23908 · Cited by 7
Li, L., Liu, S., & Luo, Y. (2024) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2024.116394 · Cited by 6
Synthetic approaches and clinical application of KRAS inhibitors for cancer therapy
Jiang, M., Ma, S., Xuan, Y., & Chen, K. (2025) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2025.117626 · Cited by 6
Oncogenic dependency plays a dominant role in the immune response to cancer
Li, J., D’Amico, S., Kirillov, V., Petrenko, O., & Reich, N. C. (2023) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2308635120 · Cited by 6
“The key role of mutant KRAS in cancers of the pancreas, colon, and lungs has driven concerted efforts to target it directly, resulting in recent discoveries of bioactive KRAS inhibitors (KRAS G12C and KRAS G12D ) (1–4).”
BackgroundExploring Protein Bioconjugation: A Redox-Based Strategy for Tryptophan Targeting
Yang, Q., Liu, S., Huang, W., Peng, C. Y., & Han, B. (2024) · Research · doi:10.34133/research.0410 · Cited by 6
Li, R., Huang, X., Wang, R., Ren, Z., Zhu, Y. L., Lu, T., Sun, Y., & Hao, C. (2025) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2025.117718 · Cited by 6
Sianoya, A. C., Zuo, Y., Pagba, C. V., Jakubec, J. L., Planque, S. A., Frost, J. A., Medina, P. M. B., & Gorfe, A. A. (2026) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-25-1087 · Cited by 6
Zhang, J., Zhang, J., Leung, E. L., & Yao, X. (2023) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2023.2178419 · Cited by 6
“Likewise, the recently reported JDQ443 formed a novel interaction with the II pocket of GDP-bound KRAS G12C, thereby showing selective antiproliferative activity in KRAS G12C mutant cell lines including those with the G12C/H95 double mutation [32].”
BackgroundHagenbeek, T. J., Zbieg, J. R., Smith, R., Paul, S., Gerosa, L., Torrini, C., Guarnaccia, A. D., Ong, C. C., Lacap, J. A., Ning, M., et al. (2026) · Nature Communications · doi:10.1038/s41467-026-74722-5 · Cited by 4
“A bene fi cial combination effect was also observed with SMIs targeting the RAS/MAPK pathway downstream, including KRAS (KRAS G12C : divarasib 55 , sotorasib 56 , adagrasib 57 , and JDQ-443 58 ; KRAS G12D : MRTX1133 59 ), RAF (belvarafenib 60 ), and MEK (cobimetinib 61 ) (Fig.”
Govaerts, S., Mayer-Figge, J. L., Chotia, M., Kirsch, S. F., & Gómez‐Suárez, A. (2025) · Organic Letters · doi:10.1021/acs.orglett.5c00395 · Cited by 4
Molecular recognition of ITIM/ITSM domains with SHP2 and their allosteric effect
Yan, C., Ouyang, W., Liu, L., Tang, L., Zhang, Z., Yue, X., Liang, L., Hu, J., & Luo, T. L. (2024) · Physical Chemistry Chemical Physics · doi:10.1039/d3cp03923d · Cited by 4
EGFR blockade confers sensitivity to pan-RAS inhibitors in KRAS-mutated cancers
Han, J., Yu, B., Jing, J., He, X., Hua, Y., & Xu, G. (2025) · Cellular Oncology · doi:10.1007/s13402-025-01075-4 · Cited by 6
Abdollahi, A., Favata, M. F., Weber, M., Roman, V. D., Hess, R., Hammond, K., Farren, M. R., Schaffer, M., Gilmartin, A. G., Wang, H., et al. (2025) · PLoS ONE · doi:10.1371/journal.pone.0327588 · Cited by 4
“Several companies have since developed their own KRAS G12C inhibitors, including adagrasib (MRTX849, Mirati Therapeutics) [8,9], GDC-6036 (Roche) [10], and JDQ443 (Novartis) [11].”
Lv, Y., Zhao, Z., Di, W., Liu, L., Chen, Y., Wei, S., Ji, Y., & Zhong, J. (2026) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2026.105150 · Cited by 4
Jian, C., Fu, H., Wu, W., Zhang, N., Liu, Z., Xia, Z., Luo, P., Zhang, H., & Cheng, Q. (2026) · Molecular Cancer · doi:10.1186/s12943-026-02594-w · Cited by 5
Systematic and precise interventions for KRAS-mutant cancers
Liang, J., Wu, J., Zhang, Y., Wang, H., Zheng, Y., & He, Q. (2026) · Experimental Hematology and Oncology · doi:10.1186/s40164-026-00763-7 · Cited by 4
“This suggests that the chemical space of non-covalent SII-P occupancy is promising for expanding to a broader range of allele scenarios [126].”
Wu, Y., Chmiel, A. F., & Bronson, J. J. (2026) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5c03492 · Cited by 4
Discovery of novel indazole derivatives as SOS1 agonists that activate KRAS signaling
Liu, L., Song, Z., Fan, G., Lou, L., Wang, Y., Zhang, X., & Xiong, X. (2023) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2023.117457 · Cited by 3
RAS G12C Inhibitors: Three Birds with One Stone
Seale, T. S., & Misale, S. (2024) · Cancer Discovery · doi:10.1158/2159-8290.cd-24-0175 · Cited by 4
The Potential Treatment Options and Combination Strategies of KRAS-Mutated Lung Cancer
Zhao, X., Zheng, Y., Wang, Y., Zhang, M., Dong, Z., Liu, Y., & Sun, M. (2024) · OncoTargets and Therapy · doi:10.2147/ott.s484209 · Cited by 6
“49,50 This interaction effectively locks the KRAS exon 2 p.G12C in an inactive state, inhibiting the excessive activation of the oncogenic pathway in tumors.”
D'Alessio‐Sands, L., Gaynier, J., Michel‐Milian, V., Agbowuro, A. A., & Brackett, C. M. (2025) · Drug Development Research · doi:10.1002/ddr.70042 · Cited by 6
143D, a novel selective KRASG12C inhibitor exhibits potent antitumor activity in preclinical models
Xu, L., Zheng, S.-X., Mei, L., Yang, K., Wang, Y., Zhou, Q., Kong, X., Zheng, M.-Y., Jiang, H., & Xie, C. (2023) · Acta Pharmacologica Sinica · doi:10.1038/s41401-023-01053-2 · Cited by 5
“Notably, KRAS inhibitors enhance tumor-killing activity when administered in combination with other inhibitors of the KRAS/MAPK signaling pathway [10, 18, 25, 26].”
BackgroundResultRetmana, I. A., Çelebi, N., Rijmers, J., Schinkel, A. H., Beijnen, J. H., & Sparidans, R. W. (2023) · Journal of Chromatography B · doi:10.1016/j.jchromb.2023.123964 · Cited by 3
Dyba, M. D., Denson, J.-P., & Maciag, A. E. (2024) · Methods in molecular biology · doi:10.1007/978-1-0716-3822-4_11 · Cited by 3
Metadata
- Authors
- Weiss, A., Lorthiois, E., Barys, L., Beyer, K. S., Bomio-Confaglia, C., Burks, H., Chen, X., Cui, X., de Kanter, R., Dharmarajan, L., Fedele, C., Gerspacher, M., Guthy, D. A., Head, V., Jaeger, A., Núñez, E. J., Kearns, J. D., Leblanc, C., Maira, S.-M., Murphy, J., Oakman, H., Ostermann, N., Ottl, J., Rigollier, P., Roman, D., Schnell, C., Sedrani, R., Shimizu, T., Stringer, R., Vaupel, A., Voshol, H., Wessels, P., Widmer, T., Wilcken, R., Xu, K., Zecri, F., Farago, A. F., Cotesta, S., & Brachmann, S. M.
- Affiliations
- Novartis (Switzerland) (CH)
- 2Novartis Institutes for BioMedical Research, Cambridge, Massachusetts.
- Novartis (United States) (US)
- 1Novartis Institutes for BioMedical Research, Basel, Switzerland.
- National Cancer Centre Japan (JP)
- Corresponding author
- Farago, Anna F.
- Cotesta, Simona
- ORCID
- Weiss, Andreas
- Lorthiois, Edwige
- Beyer, Kim S.
- Bomio-Confaglia, Claudio
- Burks, Heather
- Chen, Xueying
- Cui, Xiaoming
- de Kanter, Ruben
- Fedele, Carmine
- Guthy, Daniel Alexander
- Head, Victoria
- Núñez, Eloísa Jiménez
- Kearns, Jeffrey D.
- Maira, Sauveur-Michel
- Murphy, Jason
- Ostermann, Nils
- Ottl, Johannes
- Schnell, Christian
- Sedrani, Richard
- Shimizu, Toshio
- Stringer, Rowan
- Vaupel, Andrea
- Voshol, Hans
- Widmer, Toni
- Wilcken, Rainer
- Xu, Kun
- Farago, Anna F.
- Cotesta, Simona
- Brachmann, Saskia M.
- Venue
- Cancer Discovery
- Published
- 2022-04-04
- Volume
- 12
- Issue
- 6
- Pages
- 1500-1517
- ISSN
- 2159-8274 (ISSN-L)
- 2159-8290
- PMC
- PMC9394399
- OpenAlex
- W4223470164
- Semantic Scholar
- 489eedfd203fc45a3096bde22b30ab39345e0711
- Cited by
- 150
- References
- 60
- Citations by year
- 2026: 24 · 2025: 33 · 2024: 46 · 2023: 43 · 2022: 4
- FWCI
- 10.32
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Cancer Discovery (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- DORA PSI (Paul Scherrer Institute) (submittedVersion, cc-by-nc-nd)
- The Novartis Repository (Novartis) (submittedVersion)
- Funders
- Bristol-Myers Squibb
- Eli Lilly and Company
- Pfizer
- AstraZeneca
- Incyte
- Eisai
- Astellas Pharma
- PharmaMar
- SymBio Pharmaceuticals Limited
- Genentech
- Chugai Pharmaceutical
- Takeda Oncology
- Loxo Oncology
- Daiichi Sankyo Europe
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Melanoma and MAPK Pathways
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Tyrosine Phosphatases
- Keywords
- KRAS G12C, covalent KRAS inhibitor, switch-II pocket, TNO155, SHP2 inhibitors, combination therapy, patient-derived xenografts, cell line-derived xenografts, anticancer activity, drug resistance, MEK inhibition, CDK4/6 inhibition
- MeSH terms
- Enzyme Inhibitors, Humans, Indazoles, Mutation, Neoplasms, Proto-Oncogene Proteins p21(ras)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-06, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-06 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (qwen3.8-omni-flash and gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.